Editorial: Biomarkers – The kiss of death

Todd Krueger

J Commer Biotechnol 11: 109-110; doi:10.1057/palgrave.jcb.3040107

Abstract | PDF

Australian biotech companies: Navigating the maze

Timothy F Herpin, Helen Karuso and James E Foley

J Commer Biotechnol 11: 111-120; doi:10.1057/palgrave.jcb.3040108

Abstract | PDF

New Technology Transfer Block Exemption and Guidelines: A challenge for biotechnology

Tim Gunn

J Commer Biotechnol 11: 121-129; doi:10.1057/palgrave.jcb.3040109

Abstract | PDF

Survival strategies for start-ups

Dina Chaya

J Commer Biotechnol 11: 130-133; doi:10.1057/palgrave.jcb.3040110

Abstract | PDF

International mega-trends and growth prospects of the Finnish biotechnology industry: Recent economic research and policy implications

Raine Hermans, Martti Kulvik and Pekka Ylä-Anttila

J Commer Biotechnol 11: 134-145; doi:10.1057/palgrave.jcb.3040111

Abstract | PDF

Growth of Indian biotech companies, in the context of the international biotechnology industry

Utkarsh Palnitkar

J Commer Biotechnol 11: 146-154; doi:10.1057/palgrave.jcb.3040112

Abstract | PDF

Determining the value of drug development candidates and technology platforms

Kerstin M Bode-Greuel and Joachim M Greuel

J Commer Biotechnol 11: 155-170; doi:10.1057/palgrave.jcb.3040113

Abstract | PDF

Key financial trends that shape biotech business growth

Alex Pavlou and Mark Belsey

J Commer Biotechnol 11: 171-175; doi:10.1057/palgrave.jcb.3040114

Abstract | PDF

Legal and regulatory update

J Commer Biotechnol 11: 176-186; doi:10.1057/palgrave.jcb.3040115

Abstract | PDF

Financial accounts reports

Colin Aaronson

J Commer Biotechnol 11: 187-190; doi:10.1057/palgrave.jcb.3040116

Abstract | PDF

The Frankenfood Myth: How Protest and Politics Threaten the Biotech Revolution

Derek Burke

J Commer Biotechnol 11: 191-193; doi:10.1057/palgrave.jcb.3040117

Abstract | PDF